Hospitals are expressing relief over being able to administer the COVID-19 drug Veklury in outpatient settings and to be able to buy it finally at a 340B price.

FDA OKs COVID-19 Drug Veklury (remdesivir) for Outpatients, Opening the Way for 340B Pricing

Hospitals caring for patients infected with the highly infectious omicron variant of COVID-19 say they are very relieved to be getting 340B pricing finally on Gilead’s injectable antiviral medication Veklury (remdesivir).

On Friday, the U.S. Food and Drug Administration (FDA) approved Veklury for administration to outpatients with mild-to-moderate COVID-19. It previously was approved for inpatient administration only. 340B discounts apply to covered outpatient drugs only.

Hospitals filled with patients infected with the highly infectious omicron variant of COVID-19 say they are very relieved to be getting 340B pricing finally on Gilead’s injectable antiviral medication Veklury (remdesivir).

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report